Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$3.34 AUD
Change Today +0.24 / 7.74%
Volume 431.2K
As of 2:10 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

mesoblast ltd (MSB) Snapshot

Open
A$3.13
Previous Close
A$3.10
Day High
A$3.45
Day Low
A$3.10
52 Week High
09/5/14 - A$5.52
52 Week Low
08/25/15 - A$2.91
Market Cap
1.1B
Average Volume 10 Days
655.5K
EPS TTM
A$-0.37
Shares Outstanding
336.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MESOBLAST LTD (MSB)

Related News

No related news articles were found.

mesoblast ltd (MSB) Details

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

115 Employees
Last Reported Date: 08/16/15
Founded in 2004

mesoblast ltd (MSB) Top Compensated Officers

Founder, Chief Executive Officer, Managing Di...
Total Annual Compensation: A$1.8M
Chief Financial Officer
Total Annual Compensation: A$579.7K
Compensation as of Fiscal Year 2015.

mesoblast ltd (MSB) Key Developments

Mesoblast Limited Seeks Funding

Mesoblast Limited (ASX:MSB) has continued to talk to potential strategic partners and is confident of securing another cash injection in the next 12 months.

Mesoblast Limited Reports Audited Consolidated Earnings Results for the Full Year Ended June 30, 2015; Provides an Update on Important Changes to Its Phase 3 Chronic Heart Failure Program

Mesoblast Limited reported audited consolidated earnings results for the full year ended June 30, 2015. For the year, the company reported loss after tax for the year was AUD 119.4 million compared with AUD 81.0 million for the prior period. The increased loss was a result of expenses from continuing operations increasing by AUD 43.8 million from AUD 118.1 million to AUD 161.9 million. Revenue from continuing operations was AUD 23.748 million compared to AUD 25.980 million a year ago. Basic and diluted loss per share was 37.20 cents compared to 25.34 cents a year ago. Net cash outflows in operating activities were AUD 121.709 million compared to AUD 81.861 million a year ago. Payments for financial derivatives were AUD 0.939 million compared to AUD 1.483 million a year ago. Payments for business combination were AUD 2.331 million compared to AUD 35.585 million a year ago. Payments for licenses were AUD 0.248 million compared to AUD 0.468 million a year ago. The company provided an update on important changes to its Phase 3 chronic heart failure program. Following the meeting between Teva and the FDA, important changes to the Phase 3 chronic heart failure program for MPC-150-IM have been agreed. There will be a reduction in the total number of subjects to be recruited for the ongoing Phase 3 trial, using a time to first event analysis of heart failure-related major adverse cardiovascular events (HF-MACE) as the primary endpoint, from approximately 1,730 to 1,165. An interim analysis will be performed in the ongoing Phase 3 trial when 50% of the HF-MACE have occurred, which will include a test for superiority allowing for the possibility of stopping of the trial early based on overwhelming efficacy. A second, confirmatory study is planned to be conducted in parallel in an identical patient population of approximately 500 subjects using recurrent HF-MACE as the primary endpoint. The use of recurrent HF-MACE as a primary endpoint in the confirmatory study is supported by a new analysis of the completed Phase 2 trial, where patients treated with MPC-150-IM had no HF- MACE over 36 months of follow-up, compared with 11 recurrent HF-MACE in the control group (p<0.001, log rank test). This analysis will be presented in full at an upcoming cardiovascular scientific meeting. The Phase 3 program in CDLBP is recruiting well across North American sites. The company have received positive feedback from discussions with the European Medicines Agency and expect to expand the program to European sites.

Mesoblast Limited to Report Fiscal Year 2015 Results on Aug 17, 2015

Mesoblast Limited announced that they will report fiscal year 2015 results on Aug 17, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MSB:AU A$3.34 AUD +0.24

MSB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $3.22 USD +0.24
Caladrius Biosciences Inc $1.72 USD -0.015
Celyad €41.42 EUR -1.03
Cytori Therapeutics Inc $0.36 USD -0.0129
Pluristem Therapeutics Inc $1.89 USD +0.01
View Industry Companies
 

Industry Analysis

MSB

Industry Average

Valuation MSB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.0x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MESOBLAST LTD, please visit www.mesoblast.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.